← Leaderboards
Curtis Lisante Cetrulo
Massachusetts General Hospital
$1,349,065
Attributed
$4,781,485
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,781,485 · 2
By mechanism
R01$4,781,485 · 2
Top collaborators
- Michael Birnbaum4 shared
- Sally Choate Kent4 shared
- Biju Parekkadan4 shared
- Korkut Uygun4 shared
- Wilson Wong4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Korkut Uygun$11,870,153
- Anna Moore$29,133,166
- Biju Parekkadan$9,663,657
- Xandra Owens Breakefield$30,735,276
- Robyn S Klein$18,056,082
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroImmunosuppressionPerformanceSignal TransductionCellsEngineeringExperimental StudyIn VivoTechnologySynthetic BiologyAnimalsAutoantigensAutoimmune DiseasesAutoimmune ResponsesAttenuatedAnimal ModelAllogenicAnti-Inflammatory AgentsBeta CellAntigen TargetingBindingBiological MarkersBiological ModelsAllograft Rejection
Grant awards (8)
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$764,333
R01 · FY2025 · DK
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$769,703
R01 · FY2024 · DK
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$449,944
R01 · FY2024 · EB
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$674,605
R01 · FY2023 · DK
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$459,128
R01 · FY2023 · EB
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$728,516
R01 · FY2022 · DK
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$459,128
R01 · FY2022 · EB
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$476,128
R01 · FY2021 · EB